

WAKE FOREST UNIVERSITY

SCHOOL of MEDICINE
THE BOWMAN GRAY CAMPUS

OFFICE OF RESEARCH

<http://www.wfubmc.edu/or>

ADMINISTRATION

JAMES E. SMITH, PH.D.,
ASSOCIATE DEAN FOR RESEARCH
JOHN F. BUTTERWORTH, IV, M.D.,
SENIOR ADVISOR
DAVID P. FRIEDMAN, PH.D.,
DEPUTY ASSOCIATE DEAN FOR RESEARCH
CHARLES E. MCCALL, M.D.,
DEPUTY ASSOCIATE DEAN FOR RESEARCH
MARCO PAHOR, M.D.,
DEPUTY ASSOCIATE DEAN FOR RESEARCH
SHEILA L. VRANA, PH.D.,
ASSISTANT DEAN FOR RESEARCH
VICKY ZICKMUND 66402
PATTIE SMITH 60280
SARAH MABIE 64548

INSTITUTIONAL REVIEW BOARD (IRB)

WESLEY BYERLY, PHARM.D., DIRECTOR
FRANKIE FLETCHER 67252
JEANNIE TULLOCK 64781
AMANDA SURRATT 64542

GRANTS ADMINISTRATION

SHEILA L. VRANA, PH.D.,
ASSISTANT DEAN FOR RESEARCH
DAVID LYONS, PH.D.,
RESEARCH ADMINISTRATOR
AMY COMER 64549
RYAN FAVREAU 35306
KIM VARGAS 60780
ANGELA HORTON 62382

INTRAMURAL RESEARCH SUPPORT COMMITTEE (IRSC)

AMY COMER 64549
ANGELA HORTON 62382

ANIMAL CARE AND USE COMMITTEE (ACUC)

BEVERLY GREENWOOD 63407

INDUSTRY RELATIONS

TERRY STOUT, DIRECTOR
TERESA BUIE 62846
TINA PAGE 63157

ENVIRONMENTAL HEALTH AND SAFETY

DAVID A. BROWN, DIRECTOR
BIOSAFETY/INFECTION CONTROL 69375
RADIATION SAFETY 777-3180
CHEMICAL SAFETY 777-3099

ANIMAL RESOURCES PROGRAM

JEANNE WALLACE, D.V.M.,
DIRECTOR AND ATTENDING VETERINARIAN
BRUCE ROSE, M.S., M.B.A., OPERATIONS MANAGER
JAN SNYDER 64560
VICKIE HARDY, OPERATIONS MANAGER,
FRIEDBERG CAMPUS 61573

PURSUIT

RESEARCH INFORMATION BULLETIN Vol. 17, No. 4, April/May 2003

WAKE FOREST SCHOOL OF MEDICINE GAINS \$14.5 MILLION IN NIH FUNDING, RANKS 34TH

Buoyed by an increase of \$14.5 million, Wake Forest University School of Medicine ranked 34th among all medical schools in funds received from the National Institutes of Health (NIH) during the fiscal year that ended Sept. 30, 2002. It marked the highest position the school has ever achieved. The school also passed the \$100 million mark in NIH funding for the first time, reaching a total of \$104,803,817. Last year, the school ranked 35th with a total of \$90,303,296. "The 16 percent increase is really outstanding," said James E. Smith, Ph.D., associate dean for research. "It clearly demonstrates the excellence and entrepreneurial faculty that we have here in the research enterprise." Smith said the Department of Public Health Sciences "really led the way. They are responsible for about 40 percent of the gain." That department jumped from \$16.3 million to \$24.3 million and ranked second in the nation among the 54 medical schools that have similar departments. "They continue to advance us and I am very proud of them," Smith said. Other top 25 departments include Physiology/Pharmacology, 5th, Neurology, 12th, Cancer Biology, 15th, Obstetrics and Gynecology, 17th, Radiologic Sciences, 18th, Anesthesiology, 20th, Family Medicine, 21st, Pathology, 21st, and Surgical Sciences, 22nd. Public Health Sciences brought in the most money, but the Department of Internal Medicine was awarded grants totaling nearly \$15.9 million, Physiology/Pharmacology, \$15.5 million, Pathology, \$8.4 million and Neurology, nearly \$8.1 million. - Bob Conn

REMINDER

"THREE DAY RULE" FOR APPLICATIONS

Applications must be submitted for review and institutional signature not less than three days prior to the agency deadline. For example; for the upcoming **July 1** deadline, applications must have Controllers Office review of the budget and be submitted to the Office of Research by **June 25**.

CONCERN LINES

ANIMAL CARE & USE -
716-5899
RESEARCH CONDUCT -
716-0338
COMPLIANCE -
1-877-880-7888

**REGULATORY COMMITTEE
DEADLINES**

ANIMAL CARE AND USE COMMITTEE -
JUNE 6 AND JULY 3, 2003

INSTITUTIONAL REVIEW BOARD -
NOON - FRIDAYS

**INTRAMURAL RESEARCH
SUPPORT COMMITTEE
DEADLINES**

*REGULAR AND INTERIM -
SEPTEMBER 23, 2003

* Clinical studies or other
research involving humans
are encouraged

HUMANITARIAN USE DEVICES

Investigators are reminded that a humanitarian use device (HUD) requires IRB approval before it is used and that it can not be used outside its FDA labeled indications.

A humanitarian use device (HUD) is a device that is intended to benefit patients in the treatment and diagnosis of diseases or conditions that affect or is manifested in fewer than 4,000 individuals in the United States per year. A HUD is not required to have the results of scientifically valid clinical investigations demonstrating that the device is effective for its intended purpose but must have sufficient information for FDA to determine that the device does not pose an unreasonable or significant risk of illness or injury, and that the probable benefit to health outweighs the risk of injury or illness from its use, taking into account the probable risks and benefits of currently available devices or alternative forms of treatment. Additionally, the applicant must demonstrate that no comparable devices to the HUD are available to treat or diagnose the disease or condition, and that they could not otherwise bring the device to market. A HUD may only be used after IRB approval has been obtained for the use of the device. A manufacturer can advertise an approved HUD and a provider can bill for the use of an approved HUD, although third party payers such Medicare and insurance companies may have restrictions or conditions related to reimbursement for these devices.

Most importantly a HUD can not be used outside its FDA labeled indications. This means that close attention must be paid to the product labeling for a HUD and only patients who qualify under the FDA approved product labeling can be treated with the HUD. No off labeled or unlabeled use is allowed, even if supported by other published literature.

A HUD requires a full IRB submission. The submission should clearly indicate that the device is a humanitarian use device. A copy of the full FDA approved product information and the FDA humanitarian use approval letter should be included with the submission.

HOW DOES THE HIPAA PRIVACY RULE AFFECT RESEARCH?

Several HHS agencies (including NIH, OHRP, FDA, AHRQ, and CDC) have been working on HIPAA Privacy Rule educational materials for researchers and the research community. Those materials are now available to the research community at <http://privacyruleandresearch.nih.gov>.

DEAR DR. OR

Dear Dr. OR:

If subject recruitment, follow-up and data collection are complete, is IRB approval needed for the data analysis stage of a study?

Signed
Analysis Only

Dear Only,

When a research study is approved, the end of that study would be when all the activities described in the protocol are completed. Since the protocols include statistical analysis, this means that the protocol should maintain IRB approval until analysis is completed. Because manuscript preparation and submission is generally not included as a protocol activity but relies on the completion of protocol activities, maintaining IRB approval is usually necessary to write up the results.

Questions for Dr. OR should be submitted in writing to Amy Comer, Office of Research, or by e-mail: acomer@wfubmc.edu



SEEKING POSITION

RISEING JUNIOR AT NC STATE MAJORING IN BIOLOGY SEEKS VOLUNTEER POSITION IN RESEARCH LABORATORY. CONTACT SCOTT W. SUTTON, SWSUTTO2@UNITY.NCSU.EDU OR 918-6169.

RISEING JUNIOR AT DUKE UNIVERSITY MAJORING IN BIOLOGY SEEKS SUMMER POSITION IN RESEARCH LABORATORY. CONTACT ELISE DAGENBACH, EMD7@DUKE.EDU OR (919) 613-1665 OR (336) 924-6253.

RISEING SOPHOMORE AT UNIVERSITY OF CHICAGO SEEKS SUMMER POSITION IN RESEARCH LABORATORY. CURRENTLY WORKING AS LAB ASSISTANT IN A CLINICAL RESEARCH LAB. HAS EXPERIENCE EXTRACTING DNA FROM BLOOD SAMPLES. CONTACT CORBIN MEACHAM, CORBIN@UCHICAGO.EDU OR (773) 490-4268 OR (336) 724-4459.

RISEING SENIOR AT WAKE FOREST UNIVERSITY MAJORING IN HEALTH AND EXERCISE SCIENCE WITH A MINOR IN BIOLOGY SEEKS POSITION TO GAIN PATIENT CONTACT HOURS THIS SUMMER. CERTIFIED EMT AND HAS EXPERIENCE AS A NURSING ASSISTANT. CONTACT ELIZABETH BOLES AT BOLEEA0@WFU.EDU OR 758-1798.

SBIR (Small Business Innovative Research) Proposal Development - A Comprehensive Workshop

June 5, 2003
Hawthorne Inn
Registration and Agenda Online at
www.sbtcdc.org/sbir/workshop/phase2.pdf

Women's Health Educational and Research Opportunities for Clinicians and Scientists

*For upcoming conferences and lectures, visit
our calendar website at
www.wfubmc.edu/women*

WOMEN'S REPRODUCTIVE HEALTH RESEARCH CAREER DEVELOPMENT CENTERS - NICHD

The National Institute of Child Health and Human Development (NICHD) and the National Institutes of Health (NIH) Office of Research on Women's Health (ORWH) invite institutional career award applications for Women's Reproductive Health Research (WRHR) Career Development Centers. These awards will support research career development of obstetrician-gynecologists, to be known as Women's Reproductive Health Research Scholars, who have recently completed postgraduate clinical training, and who are commencing basic, translational, or clinical research relevant to women's health. The goal of this initiative is to promote the performance of research and transfer of findings that will benefit the health of women. The centers will accomplish this by bridging clinical training with research independence, increasing the number and skills of obstetrician-gynecologist investigators at awardee institutions through a mentored research experience leading to an independent scientific career addressing women's reproductive health concerns. This program will result in a well-qualified cadre of academic obstetrician-gynecologist investigators who will help strengthen the research capacity in health professional institutions and meet the need for highly skilled scientists with a clinical background who can address the increasing research opportunities in women's health. This request for applications (RFA) will use the NIH Mentored Research Scientist Development Program (K12) award mechanism

Deadline: July 29, 2003

Contact: Estella Parrott, M.D., M.P.H., (301) 496-6515, : ep61h@nih.gov

VIGILANCE:

UPDATES FROM WFUSM ENVIRONMENTAL HEALTH AND SAFETY

Pipette Disposal

Disposal of pipettes should be guided by composition and contamination. Appropriate disposal will minimize injuries and ensure the ultimate disposition meets all federal, state and local requirements.

Clean glass or plastic pipettes should be disposed in a box designed for glass disposal or a buff bag-lined cardboard box. Use of either container will minimize the potential of pipettes piercing the box and injuries to individuals handling the boxes.

Contaminated glass pipettes should be disposed in a sharps container. The impervious nature of the container prevents contact with contaminated material as well as prevents leakage of the material to the environment.

Contaminated plastic pipettes should be autoclaved in an orange autoclave bag prior to disposal to the landfill.

If you have any questions, please contact Bernie Menuey, WFUHS Biosafety/Infection Control Officer at 716-6640.

CONTROLLER'S CORNER - GRANTS MANAGEMENT

INFORMATION SESSIONS

The Controller's Office is offering free information sessions for departments about their grant accounts. The session can be customized to suit an individual department's needs. The grant accountant that handles your department's account will be part of the session. We have already been to several departments, and have had sessions that ranged from an informal "meet and greet" to ones where PIs and staff asked specific questions on policies and procedures. Call David Peddycord (3-4264) to set up this important information session.

ATTENTION: SUBCLASS 105 ACCOUNT HOLDERS (CLINICAL/DRUG STUDIES)

Are you tired of getting statement after statement of an account you wish would just go away? **Here is your chance!** If you can identify projects that are finished and you want them closed, or the balance moved to another account or you know where a deficit can be charged, email Meredith Rentz (mrentz@wfubmc.edu). She will review the project and get it closed as soon as possible. Over twenty projects were identified and closed in March from this new initiative. Many more are still out there but we need your help in identifying these projects. Reduce your efforts (and ours too!) on maintaining these accounts.

PROPOSAL PREPARATION: DID YOU KNOW...?

...when preparing proposals that the Controller's Office needs to review your budgets?

...that you can fax the budget pages, the cover sheet and NIH 398 check list (if applicable) to 6-6705 attention: David, Meredith, or Marty?

...that you can email them to David Peddycord (dpeddyco@wfubmc.edu) & Meredith Rentz (mrentz@wfubmc.edu)? (Its best to email to both David and Meredith in case one is not here.)

... that you do not have to send all of the original routing forms to the Controller's Office?

... that the Controller's Office and the Office of Research work together to make sure all budgets are reviewed and communicate often about each project?

... if you have questions regarding budget preparation or indirect cost calculations you can call Meredith or David or go to the Office of Research website (<http://www.wfubmc.edu/or/>) to find the current rates and a sample budget format?

Please remember to change your chartfield codes with internal service departments (ex. Library, Animal Resources Program, mail room etc). During month end we have an average of 1-2 days to check journals for animal charges, radioactive waste, etc., and we find old accounts being used. By changing/updating your accounts with these internal departments, you allow us more time to service your needs and reduce the number of "misposted" charges on old accounts.



NEWS FROM NIH

NIH

Revised NIH Policy on Submission of a Revised (Amended) Application

This announcement reiterates the NIH policy on the number of amended applications permitted but eliminates the two-year restriction on the receipt of those applications. The NIH does not consider any A3 or higher amendment to an application for extramural support. Beginning May 7, 2003, there is no longer a time limit for the submission of the first and second revisions (A1 and A2). This policy applies to all NIH extramural funding mechanisms. Principal investigators and their institutions need to exercise their best judgment in determining the advisability of submitting a revised application after several years have elapsed.

NIH

Delivery of Competing Grant, Cooperative Agreement, and Fellowship Applications

The Division of Receipt and Referral, Center for Scientific Review, NIH, would like to inform investigators submitting grant applications that the Zip Code 20817 specified in the grant application instructions for "Courier" delivery should not be used for Express Mail through the US Postal Service (USPS). The USPS does not deliver packages directly to the 6701 Rockledge Drive address but instead forwards them to the main mail facility of the NIH. If the "Courier" zip code is used with USPS, the application may be initially sent to a nonNIH mail facility and later routed to NIH. Thus, when tracking your package it will be noted that it was forwarded to another zip code (20892). That is normal procedure and the package will be forwarded back to the Rockledge address though there will be a delay. Consequently, all applications sent via US Postal Service for Express or regular mail should use the zip code 20892-7710, and all applications sent via courier delivery service should use the zip code 20817. Applications may not be delivered by individuals to the Center for Scientific Review.

NIA

Biospecimen Resources for Aging Research

The National Institute of Aging (NIA) supports longitudinal studies of human aging, some of which have developed repositories of biospecimens available for sharing. To facilitate access to human biospecimens and foster collaborative research with ongoing studies, the NIA announces a new website - the "NIH Virtual Repository" at <http://www.nia.nih.gov/research/repository.asp>. This website provides a central portal from which investigators can access information about human biospecimen repositories associated with extramural and intramural studies supported by the NIA. Current studies with human biospecimen repositories accessible through the NIA Virtual Repository include: the Study of Women's Health Across the Nation (SWAN); Health and Body Composition (Health ABC); and the Baltimore Longitudinal Study of Aging (BLSA). Additional studies will be added as information becomes available.

CHRISTOPHER REEVE PARALYSIS FOUNDATION

POSITION: Research Individual Small Grants

DESCRIPTION: The American Paralysis Foundation has merged with the Christopher Reeve Foundation and offers two-year awards for up to \$75,000. The goals of the program are to encourage promising new investigators to undertake research on regeneration and recovery, particularly with respect to the spinal cord; to encourage researchers who are well-established in other areas to transfer their efforts to spinal cord research; and to enable researchers with novel ideas to test their ideas, in order to develop pilot data for seeking larger awards from NIH and other funding sources.

Additional information can be found at <http://www.crfp.org>

DEADLINE: June 15, 2003

SCHERING-PLOUGH FOUNDATION

POSITION: Medical and Allied Education Grants

DESCRIPTION: The primary objective of the Foundation is to support institutional activities and programs devoted to improving the delivery of health care through quality medical and allied education. Pharmacy education is of special interest in this category and continues to receive increased support as part of the foundation's giving.

DEADLINE: July 1, 2003

AMERICAN ASSOCIATION FOR CANCER RESEARCH

POSITION: Research Grants

Avon Foundation-AACR International Scholar Awards for Breast Cancer Research - Proposals are being accepted from Principal Investigators who wish to apply for the prestigious designation as an Avon Foundation-AACR Scholar Host. The program will place promising junior faculty members, who are conducting breast cancer research in targeted regions of the world, under the mentorship of top breast cancer scientists at leading academic institutions in the U.S. for a two-year term. Scholars and Scholar Hosts will receive \$50,000 per year for each Scholar's salary, a grant of \$25,000 for direct research expenses, plus additional grants and benefits. Additional information is available at

http://www.aacr.org/2003AvonAACR_Scholar_Awards.asp.

DEADLINE: July 1, 2003

AACR-CRPF Award for Excellence in Cancer Prevention Research - This Award will be given to a scientist residing in any country in the world for seminal contributions in basic, translational, clinical, epidemiological, or behavioral science investigations in cancer prevention research that have had a major impact on the field and stimulated new directions in this important field. The winner will present an Award Lecture at the International Conference on Frontiers in Cancer Prevention research - the world's largest and most comprehensive annual meeting on all areas of cancer prevention research - and will receive an honorarium. Details are available at <http://www.aacr.org/1620.asp>

DEADLINE: July 1, 2003

Research Funding Opportunities

For all funding information contact Angela Horton, Office of Research, 623382, unless noted otherwise in the funding announcement

Research Funding Opportunities

For all funding information contact Angela Horton, Office of Research, 62382, unless noted otherwise in the funding announcement

THE MELANOMA RESEARCH FOUNDATION

POSITION: Research Grants

DESCRIPTION: The purpose of these grant awards are to support promising medical research that will further the goal of developing an effective treatment and possible cure of malignant melanoma, while encouraging a new generation of scientists and clinicians to join in this mission. Accordingly, awards will be given to young investigators who are beginning a research career emphasizing melanoma-related projects and have not yet established strong federal funding. In addition, emphasis will be placed on projects that explore innovative approaches to understanding melanoma and its treatment. Both basic and clinical research projects will be considered. Awards are for \$50,000 per year for two years. Additional information can be found at www.melanoma.org

DEADLINE: July 1, 2003

AMERICAN HEART ASSOCIATION

POSITION: National Center Programs

National Established Investigator Award - the objective of this award is to support mid-term investigators with unusual promise and an established record of accomplishments - specifically, candidates having a demonstrated commitment to cardiovascular or cerebrovascular science as indicated by prior publication history and scientific accomplishments. A candidate's career is expected to be in a rapid growth phase. At the time of award activation, the investigator is usually four years but no more than 9 years since first appointment at the Assistant Professor level or its equivalent. Awards are for up to \$100,000 per year including 10% indirect costs, for up to five years.

National Scientist Development Grant - the objective of this award is to support highly promising beginning scientists in their progress toward independence by encouraging and adequately funding research projects that can serve to bridge the gap between completion of research training and readiness for successful competition as an independent investigator. Research should focus broadly on cardiovascular function and disease, stroke, or to related basic science, clinical, bioengineering/biotechnology, and public health problems. Awards are for up to \$65,000 per year for up to four years.

Electronic submission is required. Additional information on these programs can be found at <http://www.americanheart.org>.

DEADLINE: July 14, 2003

CHARLES A. DANA FOUNDATION

POSITION: Clinical Hypotheses in Neuroimmunology

DESCRIPTION: The Foundation is pleased to announce a call for proposals for research on the interaction between the nervous system and the immune system. This program will support research designed to advance understanding of this relationship on a molecular and/or system level. Awards are for up to \$300,000 for up to three years. This program is designed to enable investigators to obtain pilot data more quickly than is possible under other funding mechanisms, in preparation for seeking larger-scale funding from other sources for further development. Additional information about this program is available at <http://www.dana.org/grants>

DEADLINE: July 27, 2003

NATIONAL ALLIANCE FOR RESEARCH ON SCHIZOPHRENIA AND DEPRESSION (NARSAD)

POSITION: Research Grants

DESCRIPTION: The NARSAD Research Grants Program support scientists conducting basic research, clinical research, or a combination of both in neurobiology.

Young Investigator Award - supports scientists at the advanced post-doctoral or assistant professor level. Awards are for \$30,000 per year for up to two years.

DEADLINE: July 25, 2003

Independent Investigator Award - supports scientists at the associate professor level. Awards are for up to \$50,000 per year for up to two years.

DEADLINE: March 5, 2004

Additional information can be found at <http://www.narsad.org>

BARTH SYNDROME FOUNDATION

POSITION: Research Grants

DESCRIPTION: The Foundation is seeking proposals for research that may shed light on any aspect of Barth Syndrome, a serious X-linked recessive condition associated with cardiomyopathy, neutropenia, skeletal muscle weakness, exercise intolerance, growth retardation, and diverse abnormalities. The Foundation is determined to find improved treatments - and ultimately a cure - for this rare and underdiagnosed disorder. Grants provide "seed" money to be used by experienced investigators for the testing of initial hypotheses and collection of preliminary data leading to successful long-term funding by NIH and other major granting institutions. Awards are for up to two years for up to \$40,000. A letter of intent is required for review, selected investigators will be invited to submit full grant applications. Additional information can be found at <http://www.barthsyndrome.org>.

DEADLINE: Letter of Intent - June 27, 2003

GLAXOSMITHKLINE

POSITION: Drug Discovery and Development Research Grant Program

DESCRIPTION: Research grants will be provided to recipients to advance programs directed at the development of inventive therapeutics for HIV/AIDS, including:

- Drugs aimed at treating infection
- Prophylactic vaccines
- Microbicides designed to prevent transmission of the virus

The research grants carry no obligation to the recipient's organization for licensure, patenting, or transfer of confidential information, although GSK may discuss the possibility of future collaboration with some applicants. Awards will be in amounts ranging from \$25,000 - \$150,000 based on merit. Complete information on how to apply is available at <http://www.ddresearchgrant.com>.

DEADLINE: July 31, 2003

Research Funding Opportunities

For all funding information contact Angela Horton, Office of Research, 623382, unless noted otherwise in the funding announcement

Research Funding Opportunities

For all funding information contact Angela Horton, Office of Research, 62382, unless noted otherwise in the funding announcement

NIAID, NIDDK, NHLBI

POSITION: Innovative Grants on Immune Tolerance - RFA: AI-03-010

DESCRIPTION: The Institutes invite applications for exploratory/developmental research project grants to support novel work on the molecular mechanisms and applications of antigen-specific immune tolerance, which is the selective and long-term inactivation of immune responses. The projects should involve a high degree of innovation, and have a clearly articulated potential to improve understanding of immune tolerance. Investigators new to immune tolerance are particularly encouraged to develop projects in this area. Research projects will be supported by the exploratory/developmental (R21) research grant mechanism, which provides the resources to carry out preliminary tests of feasibility for new research hypotheses.

DEADLINES:

Letter of Intent - June 15, 2003

Full Application - July 13, 2003

NLM

POSITION: Early Career Development Award for Informatics (K22) - PA-03-090

DESCRIPTION: This award is intended to facilitate the transition of investigators from the mentored to the independent stage of their careers by providing "protected time" for newly independent investigators to develop and receive support for their initial research programs. The award applies to biomedical informaticians who are pursuing research in basic informatics, clinical informatics, or the informatics relevant to biomedical research. This award is available only to individuals with health professional degrees. A candidate must have completed two years or more of postdoctoral, mentored research or have been in an independent position for less than two years at the time the application is submitted. The total project period may not exceed 3 years.

DEADLINES: October 1, 2003 and February 1, 2004

NINDS, NIMH

POSITION: Mentored Research Career Development Awards in AIDS Research - PA-03-086

DESCRIPTION: The Institutes invite applications for Mentored Clinical Scientist Development Awards (K08s), or Mentored Patient-Oriented Research Career Development Awards (K23s) from physicians and basic scientists interested in pursuing research related to HIV infection of the nervous system. The intent of this PA is to encourage research and career development for individuals with a strong commitment to a research career in the area of NeuroAIDS, either in one of the basic sciences relevant to NeuroAIDS or in clinically-oriented research. Research related to the neuropathogenesis, the role of viral or host genetic factors, inflammatory mechanisms, peripheral neuropathy, or neurological dysfunction in the setting of anti-retroviral therapy is of particular interest.

DEADLINES: October 1, 2003, February 1 and June 1, 2004

NINDS

POSITION: Individual Postdoctoral NRSA Fellowships in AIDS Research - PA-03-087

DESCRIPTION: The Institute invites applications for individual postdoctoral National Research Service Award fellowships (F32s) from physicians and basic scientists interested in pursuing research related to HIV infection of the nervous system. The intent of this PA is to encourage research and career development for individuals with a strong commitment to a research career in the area of NeuroAIDS or in clinically-oriented research. Research related to the neuropathogenesis, the role of viral or host genetic factors, inflammatory mechanisms, peripheral neuropathy, or neurological dysfunction in the setting of anti-retroviral therapy is of particular interest.

DEADLINES: August 5 and December 5, 2003

NICHHD, NINDS

POSITION: Emerging Technologies for the Study of Reproductive Neuroendocrinology - PA-03-079

DESCRIPTION: The Institutes invite applications dealing with nervous system control of reproduction. The purpose of this PA is to stimulate the development of new technologies and the application of existing innovative technologies to answer questions regarding the neuroendocrine control of reproduction that, up to this point, could not be answered due to limitations in technology. Applications submitted in response to this PA may propose hypothesis-driven, discovery-driven or developmental research. Projects deemed responsive to this PA include, but are not limited to basic, applied and clinical research proposals that seek to investigate the neuroendocrine control of reproduction using innovative invasive or non-invasive approaches; and projects that propose to develop new technologies to monitor neuroendocrine activity, particularly non-invasive approaches that have the potential for use in humans. This PA will use the NIH Research Project Grant (R01) and the Exploratory/Developmental Grant (R21) award mechanisms.

DEADLINES: October 1, 2003, February 1 and June 1, 2004

NINDS, NIA, NIDA, NIEHS

POSITION: Gene Discovery for Complex Neurological and Neurobehavioral Disorders - PAS-03-092

DESCRIPTION: The goal of this PA is to promote the identification of susceptibility genes for complex neurological and neurobehavioral disorders. For this PA, complex disorders are defined as those caused by the interaction of multiple genes, or by a combination of genetic and environmental risk factors. Projects focusing on any phase of the gene discovery process, from initial patient ascertainment to positional cloning, are appropriate. Novel approaches, including the use of intermediate phenotypes that potentially underlie complex disorders, are also encouraged. This PA will use the NIH research project grant (R01) and the exploratory/developmental grant (R21) award mechanism.

DEADLINES: October 1, 2003, February 1 and June 1, 2004

NIDA, NEI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDCR, NIEHS, NIMH, NINDS, NINR, NLM

POSITION: NIH Small Research Grant Program (R03)- PA-03-108

DESCRIPTION: This announcement redefines the NIH Small Grant (R03) mechanism, and extends its use to investigator-initiated applications at the above listed Institutes and Centers. The R03 award supports small research projects that can be carried out in a short period of time with limited resources. To allow for unsolicited R03 applications, the NIH has standardized the small grant application characteristics, requirements, preparation and review procedure. The common characteristics of the small grant is provision of limited funding for a short period of time. Examples of the types of projects that are supported with the R03 mechanism are as follows:

- Pilot or feasibility studies
- Secondary analysis of existing data
- Small, self-contained research projects
- Development of research methodology
- Development of new research technology

A project period of up to two years and a budget for direct costs of up to \$50,000 per year may be requested.

DEADLINES: October 1, 2003, February 1 and June 1, 2004

Research Funding Opportunities

For all funding information contact Angela Horton, Office of Research, 62382, unless noted otherwise in the funding announcement

Research Funding Opportunities

For all funding information contact Angela Horton, Office of Research, 62382, unless noted otherwise in the funding announcement

NIGMS

POSITION: Exploratory Studies for High Impact/High Risk Research - PA-03-100

DESCRIPTION: The purpose of this PA is to reannounce the NIGMS program to support exploratory, high impact/high risk research. This program attempts to broaden the base of inquiry in fundamental biomedical research by encouraging applications for research projects that involve an especially high degree of innovation and novelty, such that their potential for highly significant outcomes may be difficult to judge by the standard criteria used in evaluating R01 proposals. Research projects under this program may lack preliminary data establishing feasibility, but should present the opportunity for conceptual or technological breakthroughs. Awards are for two years for up to \$275,000.

DEADLINES: October 1, 2003, February 1 and June 1, 2004

KEY FOR DEPARTMENT OF HEALTH AND HUMAN SERVICES

(DHHS) INSTITUTES - (<http://www.nih.gov/icd/>)

AHRQ - Agency for Healthcare Research and Quality

NCCAM - National Center for Complementary and Alternative Medicine

NCI - National Cancer Institute

NCNR - National Center of Nursing Research

NCRR - National Center for Research Resources

NEI - National Eye Institute

NHLBI - National Heart, Lung and Blood Institute

NHGRI - National Human Genome Research Institute

NIAAA - National Institute on Alcohol Abuse and Alcoholism

NIA - National Institute on Aging

NIAID - National Institute of Allergy and Infectious Diseases

NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases

NIBIB - National Institute of Biomedical Imaging and Bioengineering

NICHD - National Institute of Child Health and Human Development

NIDA - National Institute on Drug Abuse

NIDCD - National Institute on Deafness and Other Communication Disorders

NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases

NIDCR - National Institute of Dental and Craniofacial Research

NIEHS - National Institute of Environmental Health Sciences

NIGMS - National Institute of General Medical Sciences

NIMH - National Institute of Mental Health

NINDS - National Institute of Neurological Disorders and Stroke

NLM - National Library of Medicine

ORWH - Office of Research on Women's Health

PURSUIT STAFF

SHEILA VRANA, PH.D.

DAVID LYONS, PH.D.

AMY COMER

